<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802723</url>
  </required_header>
  <id_info>
    <org_study_id>LIPO-202-CL-16</org_study_id>
    <nct_id>NCT01802723</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study</brief_title>
  <acronym>RESET</acronym>
  <official_title>A Dose Ranging Study of the Safety and Efficacy of LIPO-202 Healthy Patients With Subcutaneous Fat in the Periumbilical Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neothetics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neothetics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose Ranging Study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 weeks treatment</time_frame>
    <description>physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in global clinician abdominal perception scale score (baseline and 9 weeks)</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in global patient abdominal perception scale score (baseline and 9 weeks)</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in abdominal circumference (baseline and 9 weeks)</measure>
    <time_frame>9 weeks</time_frame>
    <description>abdominal circumference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Photonumeric abdominal perception scale score (baseline and 9 weeks)</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcome for abdominal perception score (baseline and 9 weeks)</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in subcutaneous abdominal adipose tissue thickness (baseline and 9 weeks)</measure>
    <time_frame>9 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">472</enrollment>
  <condition>Periumbilical Subcutaneous Adipose Tissue Reduction</condition>
  <arm_group>
    <arm_group_label>LIPO-202, Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: salmeterol xinafoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-202, Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: salmeterol xinafoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-202, High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: salmeterol xinafoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-202, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: salmeterol xinafoate</intervention_name>
    <arm_group_label>LIPO-202, Low</arm_group_label>
    <arm_group_label>LIPO-202, Mid</arm_group_label>
    <arm_group_label>LIPO-202, High</arm_group_label>
    <other_name>LIPO-202</other_name>
    <other_name>Salmeterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Placebo</intervention_name>
    <arm_group_label>LIPO-202, Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &gt;18 years of age inclusive Subcutaneous fat in the periumbilical area BMI &lt;30 kg/msq Stable
        diet and exercise and body weight

        Exclusion Criteria:

        Prior treatment of subcutaneous fat in the periumbilical area (liposuction, abdominoplasty,
        etc.) Known hypersensitivity to drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray C Maytom, MBChB, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Neothetics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>United States, California</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, California</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, California</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Illinois</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, New York</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Tennessee</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Texas</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Texas</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <disposition_first_submitted>March 5, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 5, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 26, 2015</disposition_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

